bioAffinity Technologies, Inc. (BIAF) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

bioAffinity Technologies, Inc.

BIAF

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

Medical - Diagnostics & Research

Next Earning date - 12 Aug 2025

Medical - Diagnostics & Research

Next Earning date - 12 Aug 2025

0.27USD

-0.01 ( -3.09%)

Market Open

Relative Strenght

Volume Buzz

-98%

Earning Acce

Dist 52w H.

91%

Overview Chart

Quote Panel

Updated June 16, 2025

1W -10.68 % 1M 18.20 % 3M -8.90 % 1Y -86.43 %

Key Metrics

Market Cap
7.60M
Shares Outstanding
28.46M
Share in Float
20.25M
Dividende
0

Earning Date
12 Aug 2025
Price Target
0.2669
Average Volume
12.44M
Beta
2.557

Range
0.164-2.989
Industry
Medical - Diagnostics & Research
Website
https://www.bioaffinitytech.com
Sector
Healthcare

Quote Panel

Updated June 16, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

0.89x

P/S Ratio

3.11x

P/B Ratio

0.9

Debt/Equity

-110.5%

Net Margin

$-0.7

EPS

How BIAF compares to sector?

P/E Ratio

Fundamentals

Relative Strength

BIAF

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

BIAF

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$8M

321%

2026-Revenue

$0.18

-13%

2026-EPS

$1M

44%

2026-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Hold

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q2.23

N/A

-0.20
vs -0.18

Q3.23

N/A

-0.26
vs -1.10

Q4.23

N/A

-0.26
vs -0.20

Q1.24

N/A

-0.26
vs -0.18

Q2.24

N/A

-0.19
vs -0.20

Q3.24

N/A

-0.16
vs -0.26

Q4.24

N/A

-0.21
vs -0.26

Q1.25

N/A

-0.16
vs -0.26

Q2.25

N/A

-0.10
vs -0.19

Q3.25

N/A

-0.09
vs -0.16

Sales Growth

YoY

Current

Estimates

Q2.23

+1411%

19.7K vs 1.3K

Q3.23

+25855%

298.5K vs 1.1K

Q4.23

+94231%

2.2M vs 2.3K

Q1.24

+261138%

2.4M vs 921

Q2.24

+12049%

2.4M vs 19.7K

Q3.24

+687%

2.4M vs 298.5K

Q4.24

2.2M vs 2.2M

Q1.25

-23%

1.9M vs 2.4M

Q2.25

-37%

1.5M vs 2.4M

Q3.25

-34%

1.6M vs 2.4M

Return on Equity

QoQ

Q2.23

-21%

-0.21
vs -0.16

Q3.23

-33%

-0.33
vs -0.21

Q4.23

-49%

-0.49
vs -0.33

Q1.24

-37%

-0.37
vs -0.49

Q2.24

-61%

-0.61
vs -0.37

Q3.24

-64%

-0.64
vs -0.61

Q4.24

-114%

-1.14
vs -0.64

Q1.25

-185%

-1.85
vs -1.14

Institutionnal Ownership

QoQ

Q2.23

7
vs 6

17%

Q3.23

10
vs 7

43%

Q4.23

12
vs 10

20%

Q1.24

14
vs 12

17%

Q2.24

17
vs 14

21%

Q3.24

14
vs 17

-18%

Q4.24

16
vs 14

14%

Q1.25

17
vs 16

Earnings Growth

Latest News

businesswire.com

8 hours ago

bioAffinity Technologies Reports First Quarter 2025 Results

businesswire.com

9 hours ago

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

businesswire.com

9 hours ago

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

zacks.com

13 hours ago

BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline

prnewswire.com

13 hours ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

businesswire.com

13 hours ago

bioAffinity Technologies Announces Closing of $3.25 Million Offering

Company Description

0.27USD

N/A

0.89x

3.11x

0.9

-110.5%

$-0.7

$8M

$0.18

$1M

Earnings Growth

Latest News

Latest News

Latest News

$8M

$0.18

$1M

Company Description

0.27USD

N/A

0.89x

3.11x

0.9

-110.5%

$-0.7